C4 Therapeutics, Inc. (CCCC) Stock Analysis
A live, multi-source view of C4 Therapeutics, Inc. (CCCC): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 104 employees · c4therapeutics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, C4 Therapeutics, Inc. (CCCC) had a market capitalization of $462.6M (forward -3.8) and a beta of 2.94; the shares traded in a 52-week range of $1.69 – $5.17 (38.0% over the year).
- Market cap
- $462.6M
- Enterprise value
- $265.8M
- Forward P/E
- -3.8
- Price / book
- 1.87
- EPS (trailing)
- $-0.92
- EPS (forward)
- $-1.00
- Payout ratio
- 0.0%
- 52-week range
- $1.69 – $5.17
- 52-week change
- 38.0%
- Beta
- 2.94
- Average volume
- 3.0M
- Shares outstanding
- 123.0M
- Short % of float
- 27.84%
- Profit margin
- -289.4%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, C4 Therapeutics, Inc. (CCCC) last closed at $3.44 (the last completed close before that scan).
Technicals at the scan: RSI 36 (neutral territory), price -13.1% versus its 20-day average, 20-day versus 50-day average spread +2.1%, MACD histogram -0.07.
Sentiment inputs: 67% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 79/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for CCCC in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
CCCC has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-07, rank #2, +13.27% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls C4 Therapeutics, Inc. (CCCC) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CCCC.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.